สมัครสมาชิก

The Group’s in-house developed product Socazolimab Injection was successfully launched in China

January 15, 2024, Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) announced that its in-house developed product Socazolimab Injection, was successfully launched in China and was distributed from its Guangzhou Nansha manufacturing site across the country.

The Group’s in-house developed product Socazolimab Injection was successfully launched in China

The Group’s in-house developed product Socazolimab Injection was successfully launched in China

The Group’s in-house developed product Socazolimab Injection was successfully launched in China

ดาวน์โหลดข่าวฉบับเต็ม (PDF)

ที่มา: Lee’s Pharmaceutical Holdings – News & Media

ข่าวสารอื่นๆ

Lee’s Pharm was honoured with “Most Valuable Companies in Hong Kong 2022 Awards” by Mediazone Group

November 10, 2022

Lee’s Pharm was proudly awarded the “Caring Company Logo” for four consecutive years

February 28, 2024

Lee’s Pharm Mask Donation Campaign, Sending warmth and care to the community

December 23, 2021

The New Product “Sodium Phenylbutyrate” from Lee’s Pharm — Bringing hope to rare disease patients — Lee’s Pharm participated in the Multidisciplinary Expert Seminar on Urea Cycle Disorders

Zhaoke Ophthalmology and Nevakar Entered Into A License Agreement for NVK-002 — Introducing The Eye Treatment For Slowing The Progression of Myopia in Children in Greater China, SEA and South Korea Markets

October 20, 2020

Lee’s Pharm was honoured with “2021 Top 100 Chinese Chemical Pharmaceutical Companies” Award

English